CD8A and melanoma: Other studies of malignant glioma and melanoma have shown that this treatment restores CD4+ and CD8+ effector T cells by abrogation of the immunosuppressive effect of Tregs which express these inhibitory markers and produce immunosuppressive IL-10 cytokine (36, 37).